Roger Godsiff – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Roger Godsiff on 2016-03-03.

To ask the Secretary of State for Health, pursuant to the Answer of 24 February 2016 to Question 28215, what the implications for the availability of Sativex to Multiple Sclerosis patients are of the NICE guidance that Sativex is not recommended as a treatment option.

George Freeman

The National Institute for Health and Care Excellence’s (NICE) clinical guideline on the management of multiple sclerosis, published in October 2014, does not recommend Sativex as a cost effective use of National Health Service resources.

In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.